Nasdaq

Boston Scientific's Positive SCS Trial Aids Neuromodulation

Boston Scientific Corporation 's BSX successful result from its WHISPER randomized controlled trial (RCT) further boosts its neuromodulation business. This announcement follows the recent FDA approval ...

First-of-its-Kind Study Shows Visibility into Real-Time Spinal Cord Stimulation Utilization and Supports a New Standard of Long-Term Device Management

A new study published in Neuromodulation1 demonstrates that automatic, daily remote monitoring of spinal cord stimulation (SCS) devices enables the first real-time visibility into post-implant therapy ...
Business Wire

Neuromodulation Pioneer WISE Closes EUR 15M Series C Financing Round to Launch Second Product, SCS EXPERT, for Chronic Pain

MILAN & BERLIN--(BUSINESS WIRE)--WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the ...
Business Wire

Global Neuromodulation Market Trends and Forecasts 2019-2024 - Spinal Cord Stimulation (SCS) Holds the Largest Market Share in the Internal Neuromodulation Type ...

DUBLIN--(BUSINESS WIRE)--The "Neuromodulation Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Neuromodulation is an intracranial, ...
Morningstar

Looking for Gains in Treating Pain

We’ve long viewed neuromodulation as a field that offered great promise but faced meaningful challenges to realizing that potential. Thanks to a spurt in innovation in spinal cord stimulation--the ...
Nasdaq

Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling

Medtronic plc MDT announced a major regulatory advancement in the fast-growing neuromodulation space. Per the announcement, the company received revised commercial labeling approval from the FDA for ...